Sodium-glucose cotransporter 2 inhibitors – beyond the treatment of diabetes mellitus
Szekeres Zsolt János, Stolcz Tünde, Szabados Eszter
Pécsi Tudományegyetem, Általános Orvostudományi Kar, I. sz. Belgyógyászati Klinika, Kardiológiai Prevenciós és Rehabilitációs Tanszék, Pécs
Sodium-glucose co-transporter 2 inhibitors have become one of the determinants of drug therapy for type 2 diabetes. Several clinical studies have demonstrated their positive effect in reducing cardiovascular mortality and morbidity, such as EMPA-REG OUTCOME for empagliflozin, CANVAS, CANVAS-R for canagliflozin, and DECLARE-TIMI 58 for dapagliflozin. Several hypotheses have been created to explain these cardioprotective effects. In addition to their effects on carbohydrate metabolism, they also affect many other parts of the body. In this review, we aim to present the main systemic effects of sodium glucose cotransporter 2 inhibitors.
ISSUE: CARDIOLOGIA HUNGARICA | 2020 | VOLUME 50, ISSUE 5
click here to read the full article
click here to read the pdf